Christopher Guttman-McCabe, serving as the Chief Regulatory & Communications Officer for Anterix Inc. (NASDAQ: ATEX), executed a significant divestment of company equity on June 15, 2026, according to filings submitted to the Securities and Exchange Commission (SEC). The executive sold a total of 91,437 shares of common stock, realizing proceeds of approximately $7,539,883. This transaction was not executed as a single block but rather through four distinct sales events, which collectively generated a weighted average price between $81.32 and $84.29 per share. The specific pricing for individual shares within these transactions ranged from a low of $80.98 to a high of $84.90.
The breakdown of the sales reveals a structured approach to the liquidation. The first tranche involved 35,321 shares sold at a weighted average of $81.3236, with prices fluctuating between $80.98 and $81.89. The second segment consisted of 26,411 shares, averaging $82.2727, with individual prices spanning $81.99 to $82.89. A third batch of 16,381 shares was sold at a weighted average of $83.7233, priced between $83.06 and $84.06. The final portion of the sale comprised 13,324 shares, averaging $84.2898, with prices ranging from $84.07 to $84.90.
Concurrent with these sales, Guttman-McCabe engaged in the acquisition of equity through the exercise of stock options on the same date. He acquired 122,852 shares of Anterix common stock, with a total cost of approximately $4,604,055. The exercise prices for these options varied from $25.75 to $49.39 per share. Notably, all stock options exercised were fully vested at the time of the transaction. Following the net effect of these complex transactions, Guttman-McCabe's direct holding in Anterix Inc. common stock stands at 77,807 shares.
While executive trading activity provides visibility into insider positions, the broader fundamental picture for Anterix has shown recent strength. The company reported its fiscal fourth-quarter 2026 earnings, delivering results that decisively outperformed Wall Street consensus estimates. Anterix posted earnings of $0.98 per share, a stark contrast to the anticipated loss of $0.54 per share. Revenue also exceeded projections, reaching $1.96 million against an estimated $1.47 million. Analysts viewed this earnings beat as a notable development, reflecting positively on the company's strategic initiatives.
The strong financial performance was bolstered by several operational factors, including successful spectrum monetization, improved cash collection processes, and the initial success of new product offerings. These results suggest that Anterix's strategic direction is yielding tangible financial returns. However, valuation metrics present a different perspective. According to InvestingPro analysis, which offers 11 additional exclusive tips for ATEX, the stock currently appears overvalued relative to its Fair Value. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for ATEX and 1,400+ other US equities.
For investors evaluating Anterix, the juxtaposition of insider selling against strong earnings performance requires careful consideration. The executive's liquidation of shares while simultaneously exercising options highlights complex portfolio management dynamics. Meanwhile, the company's ability to exceed revenue and earnings expectations underscores operational resilience in the communications infrastructure sector.